WELCOME TO THE NEW GENERATION
OF POCT
Quantitative immunoassay biosensor
to diagnosis cancer, cardiovascular diseases, sepsis, infectious diseases, thyroid disorders.
_edited_edited_edited.png)
Easy, Quick, Accurate
• Deliver lab-quality results
• Connected to anywhere
• Reduces the complexity
• Shorten time to diagnosis
• No matter where the testing takes place
19cm
Focuses on
the purpose of
POCT
Fully automated analysis
Once inserted into the instrument, the sample is separated into plasma by our patent technology.
In succession, the electrochemical analysis process begins.
No need for pre-processing
Self-contained consumable
Quick turnaround 3~10min
Quantify precisely
by electrochemical method
MARK-B utilizes MESIA, a patented technology of BBB inc.
Published Journal Paper
“MESIA: Magnetic force-assisted electrochemical sandwich immunoassays for quantification of prostate-specific antigen in human serum”
_ <Analytica Chimica Acta>, March, 2019
_ PhD. Hyundoo Hwang, Leader of BBB R&D Center
High expandability in test portfolio
*Not available for sale
*Scheduled to release in 2020
Connectivity!
Cloud server to communicate with MARK-B test results
POCT1-A2 protocol, HL7, FHIR® to communicate with DMS
Android 7.0-based Analyzer software